Axsome Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2021 Annual Meeting of Stockholders held on June 4, 2021. Axsome Therapeutics, Inc. is a Delaware corporation with its principal executive offices in New York, New York. The company's common stock trades on The Nasdaq Global Market under the symbol AXSM.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
Of the 37,563,882 shares entitled to vote, 29,091,590 shares (approximately 77.4%) were represented at the meeting, constituting a quorum. The following proposals were approved:
- Proposal 1 (Election of Directors): Herriot Tabuteau, M.D., and Mark Coleman, M.D., were elected as Class III directors. Dr. Tabuteau received 21,113,196 votes for, while Dr. Coleman received 15,040,575 votes for.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021, with 28,940,659 votes for.
- Proposal 3 (Executive Compensation): Stockholders approved the compensation of named executive officers on a non-binding advisory basis with 23,304,240 votes for.
- Proposal 4 (Compensation Vote Frequency): Stockholders approved an annual (one-year) frequency for future votes on executive compensation with 24,225,151 votes for.
Guidance, Outlook, and Risks
This filing does not contain management guidance, outlook, risk factors, or contingencies. For detailed information regarding the proposals, the filing refers investors to the definitive proxy statement on Schedule 14A filed on April 23, 2021.
Key Facts for Investor Verification
- Verify the specific terms of the director elections and the tenure of the newly elected Class III directors (until the 2024 annual meeting).
- Review the Schedule 14A Proxy Statement filed on April 23, 2021, for detailed rationale behind executive compensation and auditor selection.
- Note that 4,740,182 broker non-votes were recorded for the director election and executive compensation proposals, indicating shares held by brokers that did not receive voting instructions.
- Confirm that the company has no immediate financial disclosures in this specific 8-K filing; financial performance data should be sought in the most recent 10-K or 10-Q filings.